Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2010072630) MEDICAL USE OF RIBOSOMAL PROTEIN S19 (RPS19)
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2010/072630 International Application No.: PCT/EP2009/067265
Publication Date: 01.07.2010 International Filing Date: 16.12.2009
IPC:
A61K 38/17 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
Applicants:
JUSTUS-LIEBIG-UNIVERSITÄT GIEßEN [DE/DE]; Ludwigstraße 23 35390 Gießen, DE (AllExceptUS)
MEINHARDT, Andreas [DE/DE]; DE (UsOnly)
KLUG, Jörg [DE/DE]; DE (UsOnly)
Inventors:
MEINHARDT, Andreas; DE
KLUG, Jörg; DE
Agent:
STUMPF, Peter; Kerkrader Str. 3 35394 Gießen, DE
Priority Data:
10 2008 063 046.223.12.2008DE
Title (DE) MEDIZINISCHE VERWENDUNG DES RIBOSOMALEN PROTEINS S19 (RPS19)
(EN) MEDICAL USE OF RIBOSOMAL PROTEIN S19 (RPS19)
(FR) UTILISATION MÉDICALE DE LA PROTÉINE RIBOSOMALE S19 (RPR19)
Abstract:
(DE) Die Erfindung betrifft die Verwendung des ribosomalen Proteins S19 (Symbol: RPS19, HGNC ID:10402, Alias: DBA), das die proinflammatorische und procarcinogene Wirkung von MIF inhibiert, als Stoff zur Herstellung eines Mittels zur Behandlung akuter und chronisch entzündlicher Erkrankungen sowie Krebserkrankungen.
(EN) The invention relates to the use of ribosomal protein S19 (symbol: RPS19, HGNC ID:10402, alias: DBA), which inhibits the proinflammatory and procarcinogenic effects of MIF, as a material for producing a means for treating acute and chronic inflammatory diseases and cancer diseases.
(FR) L'invention porte sur l'utilisation de la protéine ribosomale S19 (symbole : RPS19, HGNC ID : 10402, Alias : DBA), qui inhibe l'effet pro-inflammatoire et pro-carcinogène de MIF, en tant que substance pour la fabrication d'un agent de traitement de maladies inflammatoires aiguës et chroniques ainsi que de cancers.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: German (DE)
Filing Language: German (DE)